(Last updated : 2020-07-09 09:57:27)
  Kaku Kohei
   Department     ,
   Position  
■ Present specialized field
Metabolism and endocrinology 
■ Journal
1. 2020 Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. 
2. 2020 Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the SGLT2 inhibitor, tofogliflozin, in relation to weight loss. 
3. 2020 Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial. 
4. 2020 Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance. 
5. 2020 Insulin allergy brought out 8 years after starting insulin therapy in a subject with type 1 diabetes mellitus. 
Display all(310)
■ Presentation
1. 3012/12/05 New directions in treatment of type 2 diabetes  
2. 2014/11/22 ADDITION OF LIRAGLUTIDE TO OAD MONOTHERAPY IN JAPANESE SUBJECTS WITH TYPE 2 DIABETES:
THE LIRA-ADD2OAD JAPAN TRIAL  
3. 2014/11/13 COMBINATION THERAPY WITH LIRAGLUTIDE AND INSULIN IN JAPANESE SUBJECTS WITH TYPE 2
DIABETES: THE LIRA-ADD2INSULIN JAPAN TRIAL  
4. 2014/09/12 New directions in treatment of type 2 diabetes in Japan
~ a role of SGLT2 inhibitors~  
5. 2013/09/24 Molecular mechanism of protective effect by pioglitazone and/or liraglutide on beta cell damage with the progression of diabetic morbidity  
Display all(93)